MX2022016458A - Tratamiento de la obesidad con inhibidores del receptor 75 acoplado a proteínas g (gpr75). - Google Patents
Tratamiento de la obesidad con inhibidores del receptor 75 acoplado a proteínas g (gpr75).Info
- Publication number
- MX2022016458A MX2022016458A MX2022016458A MX2022016458A MX2022016458A MX 2022016458 A MX2022016458 A MX 2022016458A MX 2022016458 A MX2022016458 A MX 2022016458A MX 2022016458 A MX2022016458 A MX 2022016458A MX 2022016458 A MX2022016458 A MX 2022016458A
- Authority
- MX
- Mexico
- Prior art keywords
- obesity
- gpr75
- coupled receptor
- protein coupled
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042327P | 2020-06-22 | 2020-06-22 | |
| US202063066185P | 2020-08-15 | 2020-08-15 | |
| US202063075858P | 2020-09-09 | 2020-09-09 | |
| US202063089625P | 2020-10-09 | 2020-10-09 | |
| US202063104613P | 2020-10-23 | 2020-10-23 | |
| US202163142632P | 2021-01-28 | 2021-01-28 | |
| US202163159017P | 2021-03-10 | 2021-03-10 | |
| US202163210287P | 2021-06-14 | 2021-06-14 | |
| US202163211061P | 2021-06-16 | 2021-06-16 | |
| PCT/US2021/038260 WO2021262601A1 (en) | 2020-06-22 | 2021-06-21 | Treatment of obesity with g-protein coupled receptor 75 (gpr75) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016458A true MX2022016458A (es) | 2023-04-05 |
Family
ID=76943116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016458A MX2022016458A (es) | 2020-06-22 | 2021-06-21 | Tratamiento de la obesidad con inhibidores del receptor 75 acoplado a proteínas g (gpr75). |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11359246B2 (https=) |
| EP (1) | EP4168548A1 (https=) |
| JP (1) | JP2023531935A (https=) |
| KR (1) | KR20230041709A (https=) |
| CN (1) | CN116249787A (https=) |
| AU (1) | AU2021296270A1 (https=) |
| CA (1) | CA3186576A1 (https=) |
| IL (1) | IL298930A (https=) |
| MX (1) | MX2022016458A (https=) |
| WO (1) | WO2021262601A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11359246B2 (en) * | 2020-06-22 | 2022-06-14 | Regeneron Pharmaceuticals, Inc. | Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors |
| EP4225917A1 (en) * | 2020-10-05 | 2023-08-16 | Alnylam Pharmaceuticals, Inc. | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
| US20250367321A1 (en) * | 2022-06-24 | 2025-12-04 | The Regents Of The University Of California | Compositions and methods involving adgrg6 |
| WO2025176787A1 (en) | 2024-02-22 | 2025-08-28 | Orion Biotechnology Holding Sa | Ccl5 variants for modulating gpr75 |
| CN120624452B (zh) * | 2025-08-12 | 2025-11-14 | 苏州吉玛基因股份有限公司 | 一种抑制GPR75基因表达的siRNA及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005040790A2 (en) * | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75) |
| US20080108145A1 (en) | 2006-11-07 | 2008-05-08 | Stephanie Chissoe | Genes associated with osteoarthritis |
| US20080108080A1 (en) * | 2006-11-07 | 2008-05-08 | Stephanie Chissoe | Genes associated with obesity |
| EP1961825A1 (en) | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
| US10446261B1 (en) | 2008-01-06 | 2019-10-15 | Biotailor, Inc. | System and method for analyzing splicing codes of spliceosomal introns |
| US8185323B1 (en) | 2008-01-06 | 2012-05-22 | Degen Zhuo | Method of identifying exons and introns and diagnostic uses thereof |
| US20110177964A1 (en) | 2009-12-03 | 2011-07-21 | The Trustees Of Princeton University | Chemosensory arrays |
| EP2763540A4 (en) * | 2011-09-09 | 2015-04-22 | Univ Yale | COMPOSITIONS AND METHODS FOR THE EVALUATION AND TREATMENT OF INFLAMMATORY DISEASES AND DISEASES |
| US20140377278A1 (en) | 2012-01-10 | 2014-12-25 | Yale University | Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders |
| WO2015017656A1 (en) | 2013-07-31 | 2015-02-05 | The Regents Of The University Of California | Methods of diagnosis and treatment for pulmonary arterial hypertension |
| WO2017004153A1 (en) | 2015-06-29 | 2017-01-05 | The Broad Institute Inc. | Tumor and microenvironment gene expression, compositions of matter and methods of use thereof |
| US20230000912A1 (en) | 2016-01-25 | 2023-01-05 | The Broad Institute, Inc. | Genetic, developmental and micro-environmental programs in idh-mutant gliomas, compositions of matter and methods of use thereof |
| US11690825B2 (en) * | 2016-03-09 | 2023-07-04 | Board Of Regents, The University Of Texas System | 20-HETE receptor (GPR75) antagonists and methods of use |
| WO2017176672A1 (en) | 2016-04-04 | 2017-10-12 | The Regents Of The University Of California | Compositions and methods related to polycytotoxic t cells |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| CN118108847A (zh) | 2016-08-07 | 2024-05-31 | 诺华股份有限公司 | mRNA介导的免疫方法 |
| US20200113950A1 (en) | 2017-06-30 | 2020-04-16 | The Rockefeller University | Human microbiota derived N-acyl amides for the treatment of human disease |
| WO2019036753A1 (en) | 2017-08-22 | 2019-02-28 | Monash University | SCREENING TESTS, MODULATORS AND MODULATION OF RECEIVER ACTIVATION FOR ADVANCED GLYCATION TERMINAL PRODUCTS (RAGE) |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020118363A1 (en) | 2018-12-10 | 2020-06-18 | Monash University | Screening assays, modulators and modulation of intracellular signalling mediated by immunoglobulin superfamily cell adhesion molecules |
| WO2020247220A1 (en) | 2019-06-03 | 2020-12-10 | University Of Florida Research Foundation, Inc. | Compositions and methods for predicting susceptibility of cancers to synthetic-lethal therapies |
| US11359246B2 (en) * | 2020-06-22 | 2022-06-14 | Regeneron Pharmaceuticals, Inc. | Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors |
-
2021
- 2021-06-21 US US17/353,313 patent/US11359246B2/en active Active
- 2021-06-21 AU AU2021296270A patent/AU2021296270A1/en active Pending
- 2021-06-21 EP EP21742592.5A patent/EP4168548A1/en active Pending
- 2021-06-21 KR KR1020237002641A patent/KR20230041709A/ko active Pending
- 2021-06-21 MX MX2022016458A patent/MX2022016458A/es unknown
- 2021-06-21 JP JP2022579077A patent/JP2023531935A/ja active Pending
- 2021-06-21 WO PCT/US2021/038260 patent/WO2021262601A1/en not_active Ceased
- 2021-06-21 IL IL298930A patent/IL298930A/en unknown
- 2021-06-21 CN CN202180051355.1A patent/CN116249787A/zh active Pending
- 2021-06-21 CA CA3186576A patent/CA3186576A1/en active Pending
-
2022
- 2022-05-19 US US17/748,110 patent/US20220411870A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220411870A1 (en) | 2022-12-29 |
| IL298930A (en) | 2023-02-01 |
| CN116249787A (zh) | 2023-06-09 |
| US20220042101A1 (en) | 2022-02-10 |
| WO2021262601A1 (en) | 2021-12-30 |
| US11359246B2 (en) | 2022-06-14 |
| KR20230041709A (ko) | 2023-03-24 |
| CA3186576A1 (en) | 2021-12-30 |
| EP4168548A1 (en) | 2023-04-26 |
| AU2021296270A1 (en) | 2023-02-02 |
| JP2023531935A (ja) | 2023-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022016458A (es) | Tratamiento de la obesidad con inhibidores del receptor 75 acoplado a proteínas g (gpr75). | |
| MX2023007012A (es) | Metodos para tratar los trastornos metabolicos y las enfermedades cardiovasculares con inhibidores de la subunidad beta e de la inhibina (inhbe). | |
| WO2020154268A3 (en) | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors | |
| Birklein et al. | Complex regional pain syndrome—phenotypic characteristics and potential biomarkers | |
| CY1118566T1 (el) | Διαγνωση με χρηση ιντερφερονης τυπου 1 | |
| BR112017021305A2 (pt) | dispositivo de teste de fluxo lateral, e, método e kit para detecção quantitativa de um analito em uma amostra de saliva | |
| Hayashi et al. | Muscular mechanical hyperalgesia after lengthening contractions in rats depends on stretch velocity and range of motion | |
| MX2022000128A (es) | Desarrollo de clasificadores para estratificar pacientes. | |
| MX2020000186A (es) | Ensayos para evaluar los niveles de anticuerpos neutralizantes en sujetos tratados con un fármaco biológico y usos de los mismos en medicina personalizada. | |
| BRPI0912927A2 (pt) | "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo" | |
| ATE419516T1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
| JOP20190199B1 (ar) | استخدام العوامل الحيوية في تحديد مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط prmt5 | |
| NZ766385A (en) | Biomarkers of methotrexate-induced immune tolerance | |
| EP4552696A3 (en) | Methods for predicting drug responsiveness in cancer patients | |
| WO2008074029A3 (en) | Protein profile for osteoarthritis | |
| DE60239012D1 (de) | Verfahren zum identifizieren von mustern in biologischen systemen und deren anwendungen | |
| PT110526B (pt) | Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais | |
| Sebastian et al. | A novel in vitro assay for electrophysiological research on human skin fibroblasts: degenerate electrical waves downregulate collagen I expression in keloid fibroblasts | |
| EP4317456A3 (en) | Piezo type mechanosensitive ion channel component 1 (piezo1) variants and uses thereof | |
| EA202192176A1 (ru) | Нарушения, опосредованные интерфероном i типа | |
| MX2021009281A (es) | Metodos de deteccion de legionella. | |
| EA202090439A1 (ru) | Способы и материалы для оценки и лечения рака | |
| MX2023001914A (es) | Tratamiento de la obesidad en sujetos que tienen variantes de moleculas de acido nucleico que codifican el receptor de calcitonina (calcr). | |
| NZ780568A (en) | Treatment of hyperglycemia with solute carrier family 39 member 5 (slc39a5) inhibitors | |
| NZ777336A (en) | Treatment of respiratory disorders with arachidonate 15-lipoxygenase (alox15) inhibitors |